6-6 fused bicyclic heteroaryl compounds and their use as LATS inhibitors

US11458138B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Dirk Behnke · Weil am Rhein, DE
• Frada BERENSHTEYN · Woburn, US
• Xueshi Hao · San Diego, US
• Timothy Z. Hoffman · San Diego, US
• Qihui Jin · San Diego, US
• Arnaud Lacoste · Cambridge, US
• Cameron Chuck-munn Lee · Cambridge, US
• Jun O. Liu · Clarksville, US
• Yahu Arthur Liu · San Diego, US
• Juergen Klaus Maibaum · Basel, CH
• Tingting MO · Saratoga, US
• Jianfeng PAN · San Diego, US
• Xin QU · Cambridge, US
• Jan TCHORZ · Basel, CH
• Yun Feng Xie · Carlsbad, US
• Shanshan YAN · San Diego, US
• Yefen Zou · San Diego, US

Key dates

• Filing date: Apr 26, 2018
• Grant date: Oct 4, 2022
• Expiry date: Nov 13, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2502/27
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention is related to 6-6 Fused Bicyclic Heteroaryl Compounds of the Formula A2 or A1 and their Use as LATS Inhibitors, or a salt, stereoisomer or pharmaceutical composition thereof; wherein the variables are as defined herein. The present invention further relates to a method of LATS inhibition in a cell population using a compound of Formula A1, or a salt, stereoisomer or pharmaceutical composition thereof. The present invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, their use in the treatment and management of diseases or disorders.